Recent Finacing
Recent Raise
Intezyne Technologies is a clinical-stage biopharma developing IT-139, a Cancer Resistance Pathway inhibitor for pancreatic and gastric cancers, and IT-141, a topoisomerase I inhibitor, advancing through Phase 1/2 trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor